IRMD iRadimed Corporation

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * McDonnell Leslie L	2. Issuer Name and Ticker or Trading Symbol IRADIMED CORP [ IRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below) Former CEO & Director
(Last)          (First)          (Middle) C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR.	3. Date of Earliest Transaction (MM/DD/YYYY) 5/28/2020
(Street) WINTER SPRINGS, FL 32708 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	5/28/2020		M(1)		101936	A	$0	151936	D
Common Stock	5/28/2020		F		30603 (2)	D	$22.31	121333	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	5/28/2020		M (1)			2867 (2)	(4)	(4)	Common Stock	7284	$0	4417	D
Restricted Stock Units	(3)	5/28/2020		M (1)			27736 (2)	(4)	(4)	Common Stock	94652	$0	71333	D
Stock Option (Right to Buy)	$21.13							(5)	(6)	Common Stock	50000		121333	D

Explanation of Responses:
(1)	As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").
(2)	Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units.
(3)	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
(4)	All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.
(5)	Pursuant to Employment Agreement, all stock options are fully vested as of the Separation Date.
(6)	Pursuant to Employment Agreement, all stock options will expire on August 26, 2020.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
McDonnell Leslie L C/O IRADIMED CORPORATION 1025 WILLA SPRINGS DR. WINTER SPRINGS, FL 32708				Former CEO & Director

Signatures
/s/ Leslie McDonnell		6/1/2020
**Signature of Reporting Person		Date